OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Beltran on the Utility of Liquid Biopsies Versus Tissue Biopsies in CRPC-NE

April 8th 2020

Himisha Beltran, MD, discusses the utility of liquid biopsies versus tissues biopsies in castration-resistant neuroendocrine prostate cancer.

Dr. Marshall on the Push Toward Precision Medicine in CRC

April 8th 2020

John L. Marshall, MD, discusses the push toward precision medicine in colorectal cancer.

Dr. Oh on the Role of Radiopharmaceuticals in mCRPC

April 8th 2020

William K. Oh, MD, discusses the role of radiopharmaceuticals in metastatic castration-resistant prostate cancer.

Dr. O'Reilly on the Role of Germline Testing in Pancreatic Cancer

April 7th 2020

Eileen O'Reilly, MD, discusses germline testing in pancreatic cancer.

Dr. Grivas on Potential Combinations With Cabazitaxel in Prostate Cancer

April 7th 2020

Petros Grivas, MD, PhD, discusses potential combination regimens with cabazitaxel in prostate cancer.

Dr. Otterson on When to Start Immunotherapy in NSCLC

April 7th 2020

Gregory A. Otterson, MD, discusses when to start treatment with immunotherapy in patients with non–small cell lung cancer.

Dr. Danilov on Venetoclax Plus BTK Inhibitors in CLL

April 7th 2020

Alexey V. Danilov, MD, PhD, discusses the potential for combining venetoclax with novel BTK inhibitors in chronic lymphocytic leukemia.

Dr. Tolaney on Sequencing Questions in Breast Cancer

April 7th 2020

Sara M. Tolaney, MD, MPH, discusses remaining sequencing questions in breast cancer.

Dr. Merritt on Robotic Lobectomy Versus VATS and Open Thoracotomy in NSCLC

April 7th 2020

Robert E. Merritt, MD, FACS, discusses the long-term oncologic outcomes of robotic lobectomy versus video-assisted thoracoscopic surgery and open thoracotomy in early-stage non-small-cell lung cancer.

Dr. Cortes on the Safety Profile of Ruxolitinib in MPNs

April 7th 2020

Jorge E. Cortes, MD, discusses the safety profile of ruxolitinib in patients with myeloproliferative neoplasms.

Dr. Denduluri on Treatment Approaches in Early-Stage HR+/HER2- Breast Cancer

April 7th 2020

Neelima Denduluri, MD, shares treatment approaches in patients with early-stage hormone receptor-positive, HER2-negative breast cancer.

Dr. Wang on Ongoing Research in MCL

April 7th 2020

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses ongoing research in mantle cell lymphoma (MCL).

Dr. Barr on Umbralisib/Ublituximab/Venetoclax in Relapsed/Refractory CLL

April 7th 2020

Paul M. Barr, MD, Wilmot Cancer Institute, University of Rochester, discusses the results of a phase I/II study evaluating the combination of umbralisib, ublituximab, and venetoclax (Venclexta) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL).

Dr. Coffman on Safety Concerns With PARP Inhibitors in Ovarian Cancer

April 7th 2020

Lan G. Coffman, MD, PhD, assistant professor at the University of Pittsburgh Medical (UPMC) Center Hillman Cancer Center, discusses safety concerns with PARP inhibitors in ovarian cancer.

Dr. Boisen on Selecting Patients for Surgery Versus Neoadjuvant Chemotherapy in Ovarian Cancer

April 7th 2020

Michelle M. Boisen, MD, discusses criteria for selecting patients with ovarian cancer for upfront surgery versus neoadjuvant chemotherapy.

Dr. Penson on Re-Challenging With PARP Inhibition in Ovarian Cancer

April 4th 2020

Richard T. Penson, MD, MRCP, associate professor of medicine, Harvard Medical School, and clinical director of Medical Gynecologic Oncology, in the Department of Medicine, Massachusetts General Hospital, discusses re-challenging with PARP inhibition in patients with ovarian cancer.

Dr. Crew on Updated Data With Margetuximab in HER2+ Breast Cancer

April 4th 2020

Katherine D. Crew, MD, MS, director of Clinical Breast Cancer Prevention Program, Columbia University Irving Medical Center, and director of DataBase Shared Resource at Herbert Irving Comprehensive Cancer Center, Columbia University, discusses updated data with margetuximab in HER2-positive breast cancer.

Dr. Goodman on the Importance of the ECHELON-2 Data in PTCL

April 4th 2020

Aaron Goodman, MD, hematologist/oncologist and assistant professor of medicine at the University of California, San Diego, discusses the importance of the phase III ECHELON-2 data in peripheral T-cell lymphoma (PTCL).

Dr. Mok Previews Discussion Topics for the Upcoming COVID-19 Webinar

April 4th 2020

Tony S. K. Mok, MD, BMSc, FRCPC, FASCO, previews discussion topics for the upcoming webinar hosted by OncLive on the novel coronavirus 2019 (COVID-19).

Dr. Levy on Emerging Biomarkers and Corresponding Therapies in Lung Cancer

April 4th 2020

Benjamin P. Levy, MD, discusses emerging biomarkers and their respective therapies in lung cancer.